Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $31.44 USD
Change Today +1.34 / 4.45%
Volume 4.0M
As of 8:04 PM 10/2/15 All times are local (Market data is delayed by at least 15 minutes).

intrexon corp (XON) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/6/15 - $69.45
52 Week Low
10/9/14 - $15.55
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for INTREXON CORP (XON)

intrexon corp (XON) Related Businessweek News

View More BusinessWeek News

intrexon corp (XON) Details

Intrexon Corporation, a biotechnology company, operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; cell systems informatics; RheoSwitch inducible gene switch; AttSite Recombinases; protein engineering; mAbLogix; and laser-enabled analysis and processing. Intrexon Corporation has collaboration agreements with ZIOPHARM Oncology, Inc.; Synthetic Biologics, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; AquaBounty Technologies, Inc.; S & I Ophthalmic, LLC; Biological & Popular Culture, Inc.; OvaXon, LLC; Intrexon Energy Partners, LLC; and Persea Bio, LLC; and strategic collaboration and licensing agreement with Merck Serono S.A. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.

480 Employees
Last Reported Date: 03/2/15
Founded in 1998

intrexon corp (XON) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: --
Chief Financial Officer
Total Annual Compensation: $382.2K
Chief Operating Officer
Total Annual Compensation: $2.3M
Senior Vice President of Health Sector
Total Annual Compensation: $485.3K
Senior Vice President of Energy Sector
Total Annual Compensation: $341.0K
Compensation as of Fiscal Year 2014.

intrexon corp (XON) Key Developments

Intrexon and ZIOPHARM to Develop Immunotherapies for Treatment of Graft-Versus-Host Disease

Intrexon Corporation announced it has formed a new Exclusive Channel Collaboration (ECC) with ZIOPHARM Oncology, Inc. for the treatment and prevention of graft-versus-host disease (GvHD), a major complication of allogeneic hematopoietic stem-cell transplantation (HSCT) which significantly impairs the quality of life and survival of many recipients. The collaboration will focus on addressing the underlying pathologies of GvHD through engineered cell platforms to express and deliver interleukin-2 (IL-2), a cytokine critical for modulation of the immune system. Through the ECC, the companies plan to pursue engineered cell therapy strategies, used either separately or in combination, for targeted treatment of GvHD. The first approach is infusion of regulatory T cells (Tregs) conditionally expressing IL-2 utilizing Intrexon's proprietary gene control approaches such as its RheoSwitch platform. The second is deployment of orally-delivered microbe-based ActoBiotics therapeutics expressing IL-2 to modulate immune function. Allogeneic HSCT is used for the treatment of various diseases including hematological malignancies, immunological deficiencies as well as non-malignant conditions. Approximately 40 to 60% of HSCT recipients develop GvHD, either acute or chronic, when immune (graft) cells in a transplant patient recognize their engrafted host as foreign and attack the patient's (host) cells. Immunosuppressive agents and systemic steroids routinely used to treat GvHD have limited efficacy and toxicity, defining the need for safer, more effective therapies. Human studies have shown that administration of low-dose subcutaneous IL-2 in patients with steroid-refractory GvHD acts via Tregs to ameliorate its manifestations. The ECC intends to expand on the benefits of IL-2 immunotherapy under Intrexon's technologies to generate clinical-grade Tregs that can precisely deliver IL-2. In addition, the ActoBiotics platform will be harnessed for its ability to target delivery of IL-2 to the digestive tract, a site which plays a significant role in the body's immune system. These new ways of treating and preventing GvHD have the potential to broaden the number of patients eligible to receive allogeneic HSCT and also increase the number of effective donor/recipient combinations. Under the terms of the agreement, Intrexon will receive a technology access fee of $10 million in cash and reimbursement for all research and development costs. The agreement also provides for equal sharing of operating profits.

Intrexon Corporation, ZIOPHARM Oncology, Inc. - Special Call

To discuss their GvHD exclusive channel collaboration

Intrexon Corporation Appoints Corey Huck as Senior Vice President, Head of Food Sector

Intrexon Corporation announced the appointment of Corey Huck as Senior Vice President, Head of Food Sector. Mr. Huck will lead Intrexon's commercialization and development of solutions that enhance the quality, desirability, sustainability and efficiency of food and its production, across its bovine, porcine, piscine, microbial, specialty crop and insect platforms. Mr. Huck, most recently Head of U.S. Sales at Syngenta, brings to Intrexon over two decades of experience in agriculture and crop protection.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XON:US $31.44 USD +1.34

XON Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alexion Pharmaceuticals Inc $166.07 USD 0.00
Photon Technology International Inc $0.0003 USD 0.00
MorphoSys AG €60.07 EUR +0.073
XOMA Corp $0.99 USD -0.09
View Industry Companies

Industry Analysis


Industry Average

Valuation XON Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26.2x
Price/Book 7.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 26.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTREXON CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at